| abstract |
The present invention relates to RNAi agents (eg, double-stranded RNAi agents) targeting the ketohexokinase (KHK) gene and methods of using such RNAi agents to inhibit KHK expression, as well as treatment of a subject suffering from a KHK-related disorder Methods, the condition is, eg, liver disease (eg, fatty liver, steatohepatitis), dyslipidemia (eg, hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia) ), glycemic control disorders (eg, insulin resistance, diabetes), cardiovascular disease (eg, hypertension, endothelial cell dysfunction), renal disease (eg, acute kidney disorder, renal tubular dysfunction, pro-inflammatory changes in proximal tubules) ), metabolic syndrome, adipocyte dysfunction, visceral fat deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar cravings. |